The Impact of EGFR Mutation Status and Brain Metastasis for Non-Small Cell Lung Cancer Treated with Ramucirumab plus Docetaxel

OBJECTIVES: Currently, combination therapy of ramucirumab (RAM) + docetaxel (DOC) must play a more important role as a second-line treatment. Epithelial growth factor receptor (EGFR) mutation accounts for around 50% of oncogenic driver mutations in patients with advanced non-small cell lung cancer (...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Oncology
Main Authors: Furuya, Naoki, Ito, Kentaro, Sakaguchi, Tadashi, Hida, Naoya, Kakinuma, Kazutaka, Morikawa, Kei, Inoue, Takeo, Komase, Yuko, Hataji, Osamu, Mineshita, Masamichi
Formato: Artigo
Idioma:Inglês
Publicado em: S. Karger AG 2020
Assuntos:
Clinical Translational Research
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7592951/
https://ncbi.nlm.nih.gov/pubmed/32464632
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1159/000507050
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados